Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type  2 Diabetes: Post Hoc Analysis of SPARTA Japan

ConclusionsAchievement of age-defined glycaemic targets with iGlarLixi treatment for 6  months was significantly affected by increased age and body weight loss, regardless of prior insulin exposure.Trial RegistrationUMIN-CTR Trials Registry, UMIN000044126; registered 10 May  2021.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research